Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer

Aims To evaluate the clinicopathological associations and predictive value of the transcription factor NF-κB in a large series of breast cancer patients treated with neoadjuvant chemotherapy. Methods A retrospective search of a prospectively maintained database was performed to identify patients. Immunohistochemistry was used to assess the p65 subunit of NF-κB, using nuclear staining as a surrogate of activation. Results Nuclear NF-κB expression was found in 26.3% (35/133) of cases. Nuclear NF-κB staining was associated with high histological grade (p=0.05), oestrogen receptor (ER) negativity (p=0.01) and higher Ki67 index (p=0.002). Patients with nuclear NF-κB staining had a higher pathological complete response (pCR) rate than those without (26.5% vs 6.0% respectively, p=0.004); there was no significant association with clinical response or outcome. In an exploratory hypothesis-generating analysis, in the ER+/HER2− subgroup (n=43) a significantly lower clinical response rate was observed in those with nuclear NF-κB staining compared with those who had no nuclear NF-κB staining (14.3% vs 61.0%, p=0.038). There were no pCRs in ER+/ HER2− tumours. Conclusions Nuclear NF-κB expression is associated with ER negativity, higher Ki67 index and tumour grade. It was also found to be significantly associated with increased pCR but not clinical response to neoadjuvant chemotherapy.

[1]  J. Frasor,et al.  Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. , 2009, Cancer research.

[2]  A. Baldwin,et al.  Her2 Activates NF-κB and Induces Invasion Through the Canonical Pathway Involving IKKα , 2009, Oncogene.

[3]  J. Reis-Filho,et al.  Genetic characterization of breast cancer and implications for clinical management , 2009, Journal of cellular and molecular medicine.

[4]  Hong-Jin Kim,et al.  Addressing Reported Pro-Apoptotic Functions of NF-κB: Targeted Inhibition of Canonical NF-κB Enhances the Apoptotic Effects of Doxorubicin , 2009, PloS one.

[5]  J. Inoue,et al.  Constitutive activation of nuclear factor‐κB is preferentially involved in the proliferation of basal‐like subtype breast cancer cell lines , 2009, Cancer science.

[6]  Robin L. Jones,et al.  The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.

[7]  S. Mader,et al.  NF‐κB and estrogen receptor α interactions: Differential function in estrogen receptor‐negative and ‐positive hormone‐independent breast cancer cells , 2009, Journal of cellular biochemistry.

[8]  Hao Zhang,et al.  NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells , 2008, Breast Cancer Research and Treatment.

[9]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[10]  F. Rojo,et al.  Inhibition of the Canonical IKK/NFκB Pathway Sensitizes Human Cancer Cells to Doxorubicin , 2007 .

[11]  E. van Marck,et al.  NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation , 2007, British Journal of Cancer.

[12]  Urs Eppenberger,et al.  Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer , 2007, BMC Cancer.

[13]  D. Biswas,et al.  Linkage between EGFR family receptors and nuclear factor kappaB (NF‐κB) signaling in breast cancer , 2006, Journal of cellular physiology.

[14]  E. Campo,et al.  Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients , 2006 .

[15]  I. Smith,et al.  Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma , 2006, British Journal of Cancer.

[16]  G. Hortobagyi,et al.  The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  P. Barker,et al.  Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. , 2005, Cancer research.

[18]  Urs Eppenberger,et al.  Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancers , 2005 .

[19]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[20]  Debajit K. Biswas,et al.  NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis , 2004 .

[21]  J. Sundberg,et al.  Characterization of the progressive skin disease and inflammatory cell infiltrate in mice with inhibited NF-kappaB signaling. , 2004, The Journal of investigative dermatology.

[22]  W. Friedrichs,et al.  NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  David S. Park,et al.  Nuclear Factor-κB Modulates the p53 Response in Neurons Exposed to DNA Damage , 2004, The Journal of Neuroscience.

[24]  M. Dowsett,et al.  Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer , 2003, British Journal of Cancer.

[25]  Jennifer Y. Zhang,et al.  NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia , 2003, Nature.

[26]  M. Dowsett,et al.  Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[28]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[29]  D. Trisciuoglio,et al.  relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells , 2001, British Journal of Cancer.

[30]  N. Magné,et al.  Activation of Nuclear Factor κB through the IKK Complex by the Topoisomerase Poisons SN38 and Doxorubicin: A Brake to Apoptosis in HeLa Human Carcinoma Cells , 2001 .

[31]  T. Hofmann,et al.  The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. , 2000, European journal of biochemistry.

[32]  K. Vousden,et al.  Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.

[33]  M. Hung,et al.  HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.

[34]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[35]  L. Ährlund‐Richter,et al.  Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. , 1999, Cancer research.

[36]  M. Schlissel,et al.  Overexpression of RelA Causes G1 Arrest and Apoptosis in a Pro-B Cell Line* , 1999, The Journal of Biological Chemistry.

[37]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[38]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[39]  C. White,et al.  Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. , 1997, The Journal of biological chemistry.

[40]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[41]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[42]  Robin L. Jones,et al.  Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer , 2009, Breast Cancer Research and Treatment.

[43]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[44]  H. Zhang,et al.  NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. , 2008, Breast cancer research and treatment.

[45]  F. Rojo,et al.  Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. , 2007, Cell cycle.

[46]  S. Bailey,et al.  Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. , 2007, Molecular cancer therapeutics.

[47]  V. V. van Hinsbergh,et al.  Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. , 2007, European journal of cancer.

[48]  E. Campo,et al.  Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. , 2006, Endocrine-related cancer.

[49]  C. Benz,et al.  Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. , 2005, The international journal of biochemistry & cell biology.

[50]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[51]  Sankar Ghosh,et al.  NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  David S. Park,et al.  Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to DNA damage. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  M. Karin,et al.  NF-kappaB in mammary gland development and breast cancer. , 2003, Journal of mammary gland biology and neoplasia.

[54]  Jennifer Y. Zhang,et al.  NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. , 2003, Nature.

[55]  Michael Karin,et al.  NF-kappaB at the crossroads of life and death. , 2002, Nature immunology.

[56]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[57]  N. Magné,et al.  Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. , 2001, Cancer research.

[58]  R. Coffey,et al.  Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. , 2001, Oncogene.

[59]  K. Vousden,et al.  Role of NF-kappaB in p53-mediated programmed cell death. , 2000, Nature.

[60]  M. C. Hu,et al.  HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. , 2000, The Journal of biological chemistry.

[61]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.